Nozue N, Ueda Y, Haga T, Muraoka A, Ono Y, Nishiya H, Miyashita H
Second Department of Internal Medicine, School of Medicine, Teikyo University.
Jpn J Antibiot. 1987 Oct;40(10):1774-86.
Laboratory and clinical studies were performed on a new oxacephem antibiotic, flomoxef (FMOX, 6315-S). In vitro antibacterial activity of FMOX was evaluated in comparison to latamoxef (LMOX), cefmetazole (CMZ), cefazolin (CEZ) using clinically isolated strains of Gram-negative and Gram-positive bacteria. Antibacterial activities of FMOX were stronger than LMOX, CMZ, CEZ against Escherichia coli, Klebsiella but only slightly effective against Staphylococcus aureus. This antibiotic drug was administered to 5 patients consisting of 2 cases with pneumonia, one each with pyelonephritis, chronic bronchitis and urinary tract infection. The drug was given in 1 g drip infusion twice a day for 8 to 13 days. Clinical efficacies of FMOX were excellent in 1 case, good in 2, fair in 1, and unevaluable in 1. As for bacteriological effect of FMOX, organisms were eradicated in 3 cases. No side effect was noted and there was no abnormal change in laboratory findings.
对一种新型氧头孢烯类抗生素氟氧头孢（FMOX，6315-S）进行了实验室和临床研究。使用临床分离的革兰氏阴性菌和革兰氏阳性菌菌株，将氟氧头孢的体外抗菌活性与拉氧头孢（LMOX）、头孢美唑（CMZ）、头孢唑林（CEZ）进行比较评估。氟氧头孢对大肠杆菌、克雷伯菌的抗菌活性强于拉氧头孢、头孢美唑、头孢唑林，但对金黄色葡萄球菌的效果仅略有成效。该抗生素药物用于5例患者，其中2例患有肺炎，肾盂肾炎、慢性支气管炎和尿路感染各1例。药物以1g静脉滴注，每天2次，持续8至13天。氟氧头孢的临床疗效1例为优，2例为良，1例为中，1例无法评估。至于氟氧头孢的细菌学效果，3例患者的病原体被清除。未观察到副作用，实验室检查结果也无异常变化。
